Pipeline

Balanced portfolio of validated and novel targets

Dual Targeting CAR-T

Adoptive cell therapy is a rapidly emerging immunotherapeutic in which a patient’s own immune cells are engineered to fight against their cancer cells.


Target specific cells were being killed by CAR-T cells, negative cells were not killed by CAR-T cells, demonstrating antigen specific killing by CAR-T.

Immuno-modulator

Activation of certain immune cells, such as NK cells and cytotoxic T cells, can effectively eradicate tumor lesions. However, immunosuppressive cells including regulatory T cells, myeloid-derived suppressor cells, and tumor-associated macrophages may counteract this immune activation, particularly in the tumor microenvironment.

Bispecific Antibody

Cancer is a heterogeneous disease whose pathogenesis is often driven by multiple signaling pathways or genetic alterations which evolve with treatment and metastasis.